New Genome Editing Technology By Merck
Proxy-CRISPR provides more experimental options to fight today’s toughest health challenges
Passionate about solving the toughest problems in life science, Merck has found a way to make CRISPR genome editing more efficient by opening up the genome for the cutting of DNA, providing more experimental options. Called “proxy-CRISPR,” Merck’s new technique provides access to previously unreachable areas of the genome. The research, published recently in Nature Communications, is the latest milestone for Merck, which has a long history in the genome editing field. The company was the first to offer custom biomolecules for genome editing globally, and the first to manufacture arrayed CRISPR libraries, accelerating cures for diseases by allowing researchers to better explore the root causes.
More Information
Learn more about Merck’s CRISPR reagentsPress Release, 17 May 2017
Press Release, 03 August 2017
“As a leader in developing tools for genome editing, Merck’s latest technology is just one example of our commitment to do our part to solve the toughest problems in life science. We’ve been a leader in gene editing for more than a decade and will continue to make this exciting area of research a priority.”
— Udit Batra, Member of the Merck Executive Board and CEO, Life Science
— Udit Batra, Member of the Merck Executive Board and CEO, Life Science
Merck proxy-CRISPR products and methods are protected by pending patent applications in the U.S. and elsewhere.